Landry K Kamdem1, Jingyue Xi2, Brandi L Clark3, Bryana J Gregory3, Kelley M Kidwell2, Ana-Maria Storniolo4, Vered Stearns5, Daniel F Hayes6, Christina L Gersch6, James M Rae6,7, N Lynn Henry8, Daniel L Hertz9. 1. Department of Pharmaceutical Sciences, Harding University College of Pharmacy, Searcy, AR, 72149-2230, USA. lkamdem@harding.edu. 2. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. 3. Department of Pharmaceutical Sciences, Harding University College of Pharmacy, Searcy, AR, 72149-2230, USA. 4. Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA. 5. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 6. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 7. Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA. 8. Huntsman Cancer Institute, Salt Lake City, UT, USA. 9. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Abstract
PURPOSE: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI treatment in postmenopausal women with hormone receptor positive (HR+) breast cancer. METHODS:Bone health in women with HR+ breast cancer enrolled on the prospective randomizedExemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 3 BTM and 24 BMD months of treatment with either the steroidal AI exemestane or the nonsteroidal AI letrozole. DNA samples were genotyped for UGT2B17*2. RESULTS: Of the 455 subjects included in the analyses, 244 (53.6%) carried at least one copy of UGT2B17*2. UGT2B17*2 was associated with lower pre-treatment BMD at the hip (P = 0.01) and spine (P = 0.0076). Letrozole treatment was associated with a greater decrease in BMD of the hip (P = 0.03) and spine (P = 0.03) than exemestane. UGT2B17 genotype was not associated with changes in BMD from 24 months of AI treatment, though in UGT2B17*2 homozygous patients, there was a trend toward greater decreases in BMD of the spine from treatment with letrozole compared with exemestane (P = 0.05). CONCLUSION: UGT2B17*2 may be associated with lower baseline BMD in women with HR+ breast cancer. Exemestane is less detrimental to bone health than letrozole in postmenopausal women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though this finding requires independent validation.
RCT Entities:
PURPOSE:UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI treatment in postmenopausal women with hormone receptor positive (HR+) breast cancer. METHODS: Bone health in women with HR+ breast cancer enrolled on the prospective randomized Exemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 3 BTM and 24 BMD months of treatment with either the steroidal AI exemestane or the nonsteroidal AI letrozole. DNA samples were genotyped for UGT2B17*2. RESULTS: Of the 455 subjects included in the analyses, 244 (53.6%) carried at least one copy of UGT2B17*2. UGT2B17*2 was associated with lower pre-treatment BMD at the hip (P = 0.01) and spine (P = 0.0076). Letrozole treatment was associated with a greater decrease in BMD of the hip (P = 0.03) and spine (P = 0.03) than exemestane. UGT2B17 genotype was not associated with changes in BMD from 24 months of AI treatment, though in UGT2B17*2 homozygous patients, there was a trend toward greater decreases in BMD of the spine from treatment with letrozole compared with exemestane (P = 0.05). CONCLUSION:UGT2B17*2 may be associated with lower baseline BMD in women with HR+ breast cancer. Exemestane is less detrimental to bone health than letrozole in postmenopausal women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though this finding requires independent validation.
Entities:
Keywords:
Bone health; Endocrine therapy; Hormone receptor positive Breast Cancer; UGT2B17
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: Per E Lønning; Jürgen Geisler; Lars E Krag; Bjørn Erikstein; Yngve Bremnes; Anne I Hagen; Ellen Schlichting; Ernst A Lien; Erik S Ofjord; Jolanda Paolini; Anna Polli; Giorgio Massimini Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Willie Wilson; Fernando Pardo-Manuel de Villena; Beverly D Lyn-Cook; Pradeep K Chatterjee; Timothy A Bell; David A Detwiler; Rodney C Gilmore; Isis C Valladeras; Camille C Wright; David W Threadgill; Delores J Grant Journal: Genomics Date: 2004-10 Impact factor: 5.736
Authors: Paul E Goss; Peyman Hadji; Milayna Subar; Paula Abreu; Torben Thomsen; Jose Banke-Bochita Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Vikki Ho; Romain Pasquet; Shaman Luo; Gang Chen; Paul Goss; Dongsheng Tu; Philip Lazarus; Harriet Richardson Journal: Breast Cancer Res Treat Date: 2020-08-01 Impact factor: 4.872
Authors: Tara Hyder; Christopher C Marino; Sasha Ahmad; Azadeh Nasrazadani; Adam M Brufsky Journal: Front Endocrinol (Lausanne) Date: 2021-07-27 Impact factor: 5.555